Medical AI Alliance
← Company Index
Medical DevicesKOSDAQ 2940906 approvals

EOFlow Co., Ltd.

Official website

Founded in 2011 and listed on KOSDAQ in 2020, EOFlow manufactures the EOPatch wearable insulin pump for diabetes management.

As of 2026-10-10, EOFlow Co., Ltd. has 6 Korean MFDS device approvals, 1 PubMed-indexed paper on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

EOFlow was founded on September 27, 2011 and listed on KOSDAQ on September 14, 2020 as a medical device manufacturer. Using electro-osmotic pump technology, it launched the wearable insulin pump EOPatch in 2021, controlled via the ADM controller or the Narsha smartphone app. EOPatch received Korean MFDS approval in 2017 with domestic sales starting April 2021, European CE marking in May 2021 with EU sales starting September 2022, UAE approval in August 2022 and Indonesia approval in October 2022, and its sensor-separated wearable artificial pancreas system received Korean MFDS approval in January 2024.

Products & technology

  • EOPatchWearable, disposable insulin infusion device that continuously delivers insulin for blood glucose management in diabetes patients
  • Sensor-separated wearable artificial pancreas systemAutomatically delivers insulin based on glucose readings via connection with a continuous glucose monitoring system (CGMS)

Regulatory approvals

data.go.kr

6 Korean MFDS device approvals · 2015–2026

  • MFDSContinuous glucose monitoring systems, self-testing, in vivo2026-09-22
    Product approval · Class 3수허 26-225 호
  • MFDSInsulin infusion pump2024-01-30
    Product approval · Class 4제허 24-77 호
  • MFDSInsulin infusion pump2021-11-10
    Product approval · Class 4제허 21-897 호
  • MFDSInsulin infusion pump2021-03-23
    Product approval · Class 4제허 21-208 호
  • MFDSInsulin infusion pump2017-12-19
    Product approval · Class 4제허 17-959 호
  • MFDSInsulin infusion pumpRevoked2015-08-25
    Product approval · Class 4제허 15-1336 호

R&D and key agreements

Source: DART corporate disclosure

센서일체형 웨어러블 인공췌장 시스템 · 당뇨 · 개발 중단 후 재개 예정 · Development was paused in 2023 under an M&A agreement with Medtronic (US); research is set to resume following the contract's termination

웨어러블 인공신장 · 개발 계획 · US subsidiary Nephria Bio was established and exclusive rights to Drexel University's MXene nanomaterial were secured for planned development; all new market entry and R&D in the non-insulin business have been halted following litigation with Insulet (US) at the end of 2025

웨어러블 비만치료제 및 NASH치료제 · 고도비만, NASH(비알콜성지방간염) · 합작법인 설립을 통한 개발 — 이후 중단 · Joint venture San Plena was established with UK-based Imperial College London venture Zihipp for development; all new market entry and R&D in the non-insulin business have been halted following litigation with Insulet (US) at the end of 2025

비인슐린 약물전달시스템(DDS) · 개발 및 공급 사업 확장 — 이후 중단 · Subsidiary Nova Pia (formerly Pharmeo) was established to develop and supply non-insulin DDS to pharmaceutical companies; all new market entry and R&D in the non-insulin business have been halted following litigation with Insulet (US) at the end of 2025

Key disclosures

KRX KIND via OpenDART
Show 40 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 278 more patents

AI reads

MAA server logs · IP-verified
63
Times AI engines pulled EOFlow Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

4
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

59
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

12
live 2
Last 7 days
57
live 4
Last 30 days
63
live 4
All time
  • OpenAIChatGPT-Userlive4
  • OpenAIOAI-SearchBot52
  • PerplexityPerplexityBot3
  • GoogleGoogleOther2
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for EOFlow Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsMedical Devices

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

i-SENS, Inc.1 shared

Founded in 2000 and KOSDAQ-listed in 2013, i-SENS makes blood glucose monitors and point-of-care testing devices.

SD BIOSENSOR INC.1 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

INTEROJO CO. LTD.100

Interojo, founded 2000 and KOSDAQ-listed 2010, manufactures contact lenses under its Clalen brand domestically and via OEM/ODM overseas.

MITECH CO.,LTD.100

MITECH CO.,LTD., founded in 1991 and listed on KOSDAQ in 2018, makes non-vascular stents and distributes Fujifilm endoscopy equipment.

JETEMA Co.,Ltd.90

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

Corentec Co., Ltd.85

Founded in 2000 and KOSDAQ-listed in 2013, Corentec makes artificial joints; hip and knee implants exceed 85% of revenue.

NanoenTek,Inc.85

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

SEJONG MEDICAL Co.Ltd.,85

Founded in 2010 and KOSDAQ-listed in 2018, Sejong Medical manufactures laparoscopic surgical instruments.

REMEDI Inc.85

Founded in 2012 and listed on KOSDAQ in 2026, REMEDI develops portable X-ray imaging devices based on its low-dose, miniaturized X-ray technology.

Laseroptek Co., Ltd.85

KOSDAQ-listed medical device company developing the LOTUS and HELIOS laser aesthetic devices and the PALLAS vitiligo treatment device.

AIOBIO Co., Ltd.85

Develops quantitative fluorescence biomarker technology for oral disease diagnostic devices.

Optipharm.CO.,LTD85

Optipharm, founded in 2000 and KOSDAQ-listed in 2018, provides animal disease diagnostics, animal medicine, and biotech.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition